CD34 and triple-negative breast carcinoma: To further explore the anti-tumor HLX10 comparability to approved Pembrolizumab (Keytruda®), we used triple-negative breast cancer (TNBC) MDA-MD-231 model, which was orthotopically implanted in the humanized CD34+ (hu-CD34) NSGTM mice.